YM BioSciences Inc.

  • Mississauga, Ontario
- www.ymbiosciences.com
  • Biotechnology
  • Healthcare Facility
  • Medical/ Pharmaceuticals

Organization Profile

YM BioSciences Inc. is a drug development company advancing three clinical-stage products: CYT387, a small molecule, dual inhibitor of the JAK1/JAK2 kinases; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a vascular disrupting agent (VDA).

Contact Information

James Smith
VP Corporate Communications
Tel: 905-361-9518

Latest News Releases